Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Acetaminophen/Naproxen Sodium - Johnson & Johnson

Next Previous
X
Search
Drug Profile

Acetaminophen/Naproxen Sodium - Johnson & Johnson

Alternative Names: Naproxen Sodium/Acetaminophen - Johnson & Johnson

Latest Information Update: 04 Jul 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Johnson & Johnson
  • Class Acetanilides; Aminophenols; Antipyretics; Naphthaleneacetic acids; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors; Cytochrome P-450 enzyme system inhibitors; Prostaglandin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Postoperative pain

Most Recent Events

  • 30 May 2024 Johnson & Johnson completes the Phase-III clinical trials in Postoperative pain (In adolescents, In adults) in USA (PO) (NCT05761574)
  • 30 May 2024 Johnson and Johnson completes a phase III trial in Postoperative pain (In adolescent, In adults) in USA (PO, Tablet) (NCT05868122)
  • 29 Feb 2024 Johnson & Johnson withdraws a planned phase-III trial for Postoperative pain (In adolescents) in USA (PO, Tablet), since the study is no longer required due to change in development program strategy (NCT05845008)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top